NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more NanoLogix (CE) Charts. Click Here for more NanoLogix (CE) Charts.](/p.php?pid=staticchart&s=NO%5ENNLX&p=8&t=15)
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis, has today announced
that its wholly-owned medical devices subsidiary, Designer Diagnostics,
has started marketing the first-ever environmental test kit for the
detection of Nontuberculous Mycobacteria (NTM) in water and soil.
“The primary goal of these environmental test
kits is to reduce the number of NTM infections worldwide by preventing
the public’s exposure to NTM and determining
the source of origin of NTM infections in patients,”
explained Neil Roth, President of Designer Diagnostics. “In
order to accomplish this goal, we believe that every municipality,
hospital and water treatment facility should have these test kits on
hand for periodic testing of the environment,”
he added.
Nontuberculous Mycobacterium, also known as atypical Tuberculosis
(Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a
bacteria that is found in a multitude of environments - in the soil, in
some domestic and wild animals, and perhaps most importantly, in water,
including showers and hot tubs. One of the most common forms of NTM
infections found in humans is Mycobacterium avium complex (MAC). This is
a primary cause of respiratory disease in humans and is a leading cause
of death in HIV/AIDS patients.
In December, Nutra Pharma announced that it expanded its licensing
agreement with Ohio-based NanoLogix, Inc. (PINK SHEETS:NNLX) to include
additional intellectual property for the use of testing the environment
for NTM.
“All of us at NanoLogix are excited that this
beneficial technology is finally coming to market,”
said Bret Barnhizer, CEO of NanoLogix, Inc. “These
test kits will not only play an important role in reducing NTM
infections in developing nations, but will also assist in the detection
and prevention of NTM exposure and infection in the United States and
other developed countries,” he added.
Recently, distinguished NTM research scientist Dr. Rahul Narang used the
Designer Diagnostics environmental test kits to test soil and water
samples collected from the environment of patients with NTM infections.
This was the first time the technique was used in India and the findings
were presented in November at the 38th Union World Conference on Lung
Health in Cape Town, South Africa.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp., through its
subsidiaries, carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc., is developing these technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics, is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
http://www.NutraPharma.com
http://www.DesignerDiagnostics.com
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC"). The marketing of Designer Diagnostics’
environmental test kits should not be construed as an indication in any
way whatsoever of the value of the Company or its common stock. The
Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.